Compare BridgeBio Pharma Inc (BBIO) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs PAGSEG Inc — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while PAGSEG Inc trades at $9.07 (market cap $2.59B). The key difference: BridgeBio Pharma Inc is far larger — about 6.4× PAGSEG Inc's market cap, and PAGSEG Inc pays a 11.21% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | PAGS | |
|---|---|---|
Market Cap | $16.46B | $2.59B |
Sector | Health | Technology |
52-Week High | $90.17 | $12.00 |
52-Week Low | $44.81 | $7.75 |
Enterprise Value | $18.02B | $10.22B |
Dividend Yield | — | 11.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
PAGS trades at $9.28, up 0.32% on the day, with a bullish technical signal from moving averages. The stock shows strong value metrics with a P/E of 6.57 and P/S of 0.68, supported by solid profitability including a 10.4% net income margin. Recent Q1 2026 earnings missed expectations at $0.39 per share versus $0.40 expected, but Q4 2025 beat estimates. The company maintains robust cash flow from operations of $7.56 billion in 2025.
Outlook remains positive due to deep valuation discounts and analyst consensus favoring buys (62.5%). Key risks include Brazilian macroeconomic sensitivity and competitive pressures in digital banking. Upside potential hinges on execution in credit expansion and efficiency gains, with the stock positioned for recovery if rate cuts materialize in Brazil.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
